Cargando…

Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study

BACKGROUND: Irritable bowel syndrome (IBS) is one of the most common functional digestive disorders. Our understanding about its comorbidities, biomarkers, or long‐term risks is still incomplete. OBJECTIVE: To characterize comorbidities and biomarkers for IBS and establish the effect of IBS on overa...

Descripción completa

Detalles Bibliográficos
Autores principales: Seeling, Katharina Sophie, Hehl, Leonida, Vell, Mara Sophie, Rendel, Miriam Daphne, Creasy, Kate Townsend, Trautwein, Christian, Mehler, David Marc Anton, Keszthelyi, Daniel, Schneider, Kai Markus, Schneider, Carolin Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256994/
https://www.ncbi.nlm.nih.gov/pubmed/37151116
http://dx.doi.org/10.1002/ueg2.12397
_version_ 1785057225095512064
author Seeling, Katharina Sophie
Hehl, Leonida
Vell, Mara Sophie
Rendel, Miriam Daphne
Creasy, Kate Townsend
Trautwein, Christian
Mehler, David Marc Anton
Keszthelyi, Daniel
Schneider, Kai Markus
Schneider, Carolin Victoria
author_facet Seeling, Katharina Sophie
Hehl, Leonida
Vell, Mara Sophie
Rendel, Miriam Daphne
Creasy, Kate Townsend
Trautwein, Christian
Mehler, David Marc Anton
Keszthelyi, Daniel
Schneider, Kai Markus
Schneider, Carolin Victoria
author_sort Seeling, Katharina Sophie
collection PubMed
description BACKGROUND: Irritable bowel syndrome (IBS) is one of the most common functional digestive disorders. Our understanding about its comorbidities, biomarkers, or long‐term risks is still incomplete. OBJECTIVE: To characterize comorbidities and biomarkers for IBS and establish the effect of IBS on overall‐ and cause specific mortality. METHODS: We analyzed data from the population‐based cohort of the UK Biobank (UKB) with 493,974 participants, including self‐reported physician‐diagnosed (n = 20,603) and ICD‐10 diagnosed (n = 7656) IBS patients, with a mean follow‐up of 11 years. We performed a phenome‐wide association study (PheWAS) and competing risk analysis to characterize common clinical features in IBS patients. RESULTS: In PheWAS analyses, 260 PheCodes were significantly overrepresented in self‐reported physician‐diagnosed IBS patients, 633 in patients with ICD‐10 diagnosed IBS (ICD‐10‐IBS), with 221 (40%) overlapping. In addition to gastrointestinal diseases, psychiatric, musculoskeletal, and endocrine/metabolic disorders represented the most strongly associated PheCodes in IBS patients. Self‐reported physician‐diagnosed IBS was not associated with increased overall mortality and the risk of death from cancer was decreased (hazard ratio [HR] = 0.78 [95% CI = 0.7–0.9]). Lastly, we evaluated changes in serum metabolites in IBS patients and identified glycoprotein acetyls (GlycA) as a potential biomarker in IBS. One standard deviation increase in GlycA raised the risk of self‐reported IBS/ICD‐10 coded by 9%–20% (odds ratio [OR] = 1.09 [95% CI = 1.1–1.1]/OR = 1.20 [95% CI = 1.1–1.3]) and the risk of overall mortality in ICD‐10‐IBS patients by 28% (HR = 1.28 [95% CI = 1.1–1.5]). CONCLUSION: Our large‐scale association study determined IBS patients having an increased risk of several different comorbidities and that GlycA was increased in IBS patients.
format Online
Article
Text
id pubmed-10256994
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-102569942023-06-11 Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study Seeling, Katharina Sophie Hehl, Leonida Vell, Mara Sophie Rendel, Miriam Daphne Creasy, Kate Townsend Trautwein, Christian Mehler, David Marc Anton Keszthelyi, Daniel Schneider, Kai Markus Schneider, Carolin Victoria United European Gastroenterol J Neurogastroenterology BACKGROUND: Irritable bowel syndrome (IBS) is one of the most common functional digestive disorders. Our understanding about its comorbidities, biomarkers, or long‐term risks is still incomplete. OBJECTIVE: To characterize comorbidities and biomarkers for IBS and establish the effect of IBS on overall‐ and cause specific mortality. METHODS: We analyzed data from the population‐based cohort of the UK Biobank (UKB) with 493,974 participants, including self‐reported physician‐diagnosed (n = 20,603) and ICD‐10 diagnosed (n = 7656) IBS patients, with a mean follow‐up of 11 years. We performed a phenome‐wide association study (PheWAS) and competing risk analysis to characterize common clinical features in IBS patients. RESULTS: In PheWAS analyses, 260 PheCodes were significantly overrepresented in self‐reported physician‐diagnosed IBS patients, 633 in patients with ICD‐10 diagnosed IBS (ICD‐10‐IBS), with 221 (40%) overlapping. In addition to gastrointestinal diseases, psychiatric, musculoskeletal, and endocrine/metabolic disorders represented the most strongly associated PheCodes in IBS patients. Self‐reported physician‐diagnosed IBS was not associated with increased overall mortality and the risk of death from cancer was decreased (hazard ratio [HR] = 0.78 [95% CI = 0.7–0.9]). Lastly, we evaluated changes in serum metabolites in IBS patients and identified glycoprotein acetyls (GlycA) as a potential biomarker in IBS. One standard deviation increase in GlycA raised the risk of self‐reported IBS/ICD‐10 coded by 9%–20% (odds ratio [OR] = 1.09 [95% CI = 1.1–1.1]/OR = 1.20 [95% CI = 1.1–1.3]) and the risk of overall mortality in ICD‐10‐IBS patients by 28% (HR = 1.28 [95% CI = 1.1–1.5]). CONCLUSION: Our large‐scale association study determined IBS patients having an increased risk of several different comorbidities and that GlycA was increased in IBS patients. John Wiley and Sons Inc. 2023-05-07 /pmc/articles/PMC10256994/ /pubmed/37151116 http://dx.doi.org/10.1002/ueg2.12397 Text en © 2023 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Neurogastroenterology
Seeling, Katharina Sophie
Hehl, Leonida
Vell, Mara Sophie
Rendel, Miriam Daphne
Creasy, Kate Townsend
Trautwein, Christian
Mehler, David Marc Anton
Keszthelyi, Daniel
Schneider, Kai Markus
Schneider, Carolin Victoria
Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study
title Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study
title_full Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study
title_fullStr Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study
title_full_unstemmed Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study
title_short Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study
title_sort comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: a phenome‐wide association study
topic Neurogastroenterology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256994/
https://www.ncbi.nlm.nih.gov/pubmed/37151116
http://dx.doi.org/10.1002/ueg2.12397
work_keys_str_mv AT seelingkatharinasophie comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy
AT hehlleonida comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy
AT vellmarasophie comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy
AT rendelmiriamdaphne comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy
AT creasykatetownsend comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy
AT trautweinchristian comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy
AT mehlerdavidmarcanton comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy
AT keszthelyidaniel comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy
AT schneiderkaimarkus comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy
AT schneidercarolinvictoria comorbiditiesbiomarkersandcausespecificmortalityinpatientswithirritablebowelsyndromeaphenomewideassociationstudy